WALTHAM, Mass. — Thermo Fisher Scientific said it expanded its Thermo Scientific Orbitrap mass spectrometry platforms, AI-enabled software and integrated workflows at the American Society for Mass Spectrometry Conference.
The company introduced three new Orbitrap platforms designed to support research, biopharmaceutical development and applied testing markets. Thermo Fisher said the expanded portfolio is intended to help laboratories analyze complex samples, manage larger data sets and produce more confident results in areas including drug development, food safety, environmental testing and water analysis.
“Orbitrap technology has long set the standard for breakthrough discovery, and customers now want that same confidence across applied scientific markets,” said Ronald Tabaksblat, president of chromatography and mass spectrometry at Thermo Fisher Scientific. “At ASMS 2026, we are showcasing how Thermo Fisher is scaling Orbitrap innovation through connected platforms, software and workflows that support advanced research, drug development and applied testing with decision-ready results.”
For research applications, Thermo Fisher introduced the Orbitrap Tribrid Apex Mass Spectrometer, which the company described as its most versatile and highest-performing Orbitrap Tribrid system. The platform includes three mass analyzers, a new infrared laser option for alternative fragmentation and Direct Mass Technology Mode, which Thermo Fisher said can help researchers generate clearer insights from complex biological samples earlier in the discovery process.
Thermo Fisher also expanded its software capabilities for proteomics, spectral analysis and protein characterization. The company said its recent acquisitions of MSAID and Proteinaceous add AI-driven proteomics, machine learning and bioinformatics capabilities. It also introduced Proteoform Studio Software and Proteome Discoverer 3.4 Software to support deeper protein characterization and broader proteomics workflow management.
For biopharma and pharmaceutical drug development, Thermo Fisher unveiled the Orbitrap Excedion Mass Spectrometer, a platform designed for applications including drug metabolism studies and oligonucleotide and peptide analysis. The company said the system’s enhanced dynamic range can detect three to five times more compounds in complex samples and improve reproducibility across larger studies.
Thermo Fisher said laboratories will be able to upgrade to the Orbitrap Excedion Pro Mass Spectrometer without replacing their existing instrument, allowing users to expand analytical power while reducing cost and disruption.
The company also introduced related products for biopharmaceutical development labs, including Vanquish Amplify UHPLC Systems, SurePac RP MDi Columns, the SMART Digest OligoSelect Kit and BioPharma Finder 5.5 Software. Thermo Fisher said the tools are designed to improve analysis of sensitive biological molecules, support oligonucleotide, mRNA and protein therapeutic analysis, streamline sample preparation and process complex top-down mass spectrometry data.
For later-stage drug development and regulated bioanalysis, Thermo Fisher said it will showcase the TSQ Certis Triple Quadrupole Mass Spectrometer, which it said can measure samples 15% faster and operate more than twice as long between maintenance events for complex matrices such as plasma.
Thermo Fisher also introduced the Orbitrap Exploris GC S Mass Spectrometer for environmental and food safety laboratories. The high-resolution gas chromatography-mass spectrometry platform is designed for dioxin and persistent organic pollutant analysis, with the sensitivity and resolution needed for ultra-trace testing and identification of emerging contaminants.
The company said it will also showcase the Orbitrap Exploris EFOX Mass Detector for high-resolution screening of PFAS, pesticides and related contaminants, along with the TSQ Altis Plus EFOX Triple Quadrupole Mass Spectrometer for high-throughput quantitation.
Thermo Fisher said the expanded systems and workflows are intended to help research, biopharma, environmental, water and food safety laboratories detect known and emerging contaminants faster, support more confident development decisions and improve public health-related testing.
